title: The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
abstract: On 15 December 2005, the European Medicines Agency (EMEA) launched an "SME Office" to provide financial and administrative assistance to micro-, small- and medium-sized enterprises (SMEs), with the aim of promoting innovation and the development of new human and veterinary medicinal products by SMEs. According to current EU definition of an SME, companies with fewer than 250 employees, and an annual turnover of not more than 50 million euro or an annual balance sheet total of not more than 43 million euro, are eligible for assistance from the SME Office. Incentives available from the EMEA for SMEs, include: Administrative and procedural assistance from SME Office within the Agency; Fee reductions (90%) for scientific advice and inspections; Fee exemptions for certain administrative services (excluding parallel distribution); Deferral of the fee payable for an application for marketing authorisation or related inspection until after the grant of the marketing authorisation; Conditional fee exemption where scientific advice followed and marketing application is unsuccessful; Assistance with translations of the product information documents. At the end of May 2009, more than 380 companies from 21 countries across the European Economic Area (EEA) had SME status assigned by the EMEA. The large majority of companies are developing medicinal products for human use, 16 are veterinary companies, 15 companies are developing products for both human and veterinary use and 38 are regulatory consultants. Since the SME initiative started the Agency has processed more than 130 requests for scientific advice with fee reductions totalling of 6.9 million euro. Regulatory assistance has been provided to more than 170 companies and 12 companies have benefited from the SME translation service. Stakeholders have acknowledged the significant role the SME Office now plays as a service provider. In the period between January 2006 and June 2009, 34 applications for marketing authorization from SME applicants were filed for medicinal products for human use. Current analysis shows SMEs to have a lower success rate compared to non-SME companies. Major objections for SMEs are particularly high in the area of quality. Although the SME initiative is still at an early stage, it is apparent from the experience gained with applications for marketing authorisation to date that it is important for companies to open up an early dialogue with the EMEA. Scientific advice should be sought early, proactively and comprehensively on key issues in development (quality, non-clinical, clinical) and follow-up advice should be sought as development proceeds. For advanced therapy medicinal products, the assistance available to SMEs will be reinforced in 2009, with the introduction of the certification process.
authors.affiliation: SME Office, Scientific Advice and Orphan Drugs Sector Pre-Authorisation Unit, European Medicines Agency, London, United Kingdom. melanie.carr@emea.europa.eu
authors.forename: M
authors.initials: M
authors.lastname: Carr
mesh_terms: D017690:Cell Transplantation / Q000191:economics* / Q000331:legislation & jurisprudence*; D005060:Europe; D005062:European Union; D005378:Financial Support; D015316:Genetic Therapy / Q000191:economics* / Q000331:legislation & jurisprudence*; D006801:Humans; D008389:Marketing of Health Services / Q000191:economics / Q000331:legislation & jurisprudence; D017149:Private Sector / Q000191:economics* / Q000331:legislation & jurisprudence*; D023822:Tissue Engineering / Q000191:economics* / Q000331:legislation & jurisprudence*